公司于 2025 年 10 月 30 日召开了第四届董事会第八次会议，审议通过了《关 于补选公司第四届董事会非独立董事的议案》，同意提名岳瀚先生为公司第四届 董事会非独立董事候选人，任期自公司股东大会审议通过之日起至第四届董事会 任期届满之日止。 岳瀚先生的个人简历详见附件。上述议案尚需提交公司股东大会审议。 证券代码：688576 证券简称：西山科技 公告编号：2025-043 重庆西山科技股份有限公司 关于补选公司非独立董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《公司法》《公司章程》等相关规定，董事会提名委员会对第四届董事 会非独立董事候选人岳瀚先生的任职资格审查，同意提名岳瀚先生为公司第四届 董事会非独立董事候选人。 岳瀚先生个人简历 岳瀚，男，汉族，1989 年 1 月生，2010 年 7 月参加工作，硕士研究生学历。 2010 年 7 月至 2016 年 8 月任天津银行北京分行投资部经理，2018 年 3 月至 2020 年 9 月任启迪未来投资控股（北京）有限公司医疗事业部总经理助理，2 ...

Core Viewpoint - Xishan Technology (688576) has experienced a slight decline in stock price, with a current market capitalization of 2.952 billion yuan, ranking 110th in the medical device sector and 4486th in the A-share market [1] Shareholder Changes - As of September 19, 2025, the number of shareholders decreased by 3.33% to 5284, with the average shareholding increasing from 8324 shares to 8611 shares, and the average shareholding value reaching 566,200 yuan [2][4] Institutional Research Highlights - The company has established a clear plan for overseas market expansion, with products currently covering 46 countries and regions, focusing on Southeast Asia, Latin America, and countries along the Belt and Road Initiative [3][4] - The company is seeking partnerships with international medical device giants as part of its strategy for overseas market expansion, enhancing market access and distribution networks [3] - The company is considering expanding into the surgical robot field and will continue to monitor the feasibility of brain-computer interface technology [3][4] - In the first half of 2025, the company achieved revenue of 155.0358 million yuan, reflecting a year-on-year growth of 2.40%, with ongoing efforts to promote disposable consumables and expand endoscope products [3][4]

Group 1 - On September 23, Xishan Technology's stock fell by 1.44%, with a trading volume of 23.32 million yuan [1] - The financing data on the same day showed a financing purchase amount of 4.07 million yuan and a net financing purchase of 2.27 million yuan, with a total financing and securities balance of 93.61 million yuan, accounting for 6.68% of the circulating market value [1] - The company specializes in the research, production, and sales of surgical power devices, with 92.10% of its main business revenue coming from this segment [1] Group 2 - As of September 19, the number of shareholders of Xishan Technology was 5,284, a decrease of 3.33%, while the average circulating shares per person increased by 3.44% [2] - For the first half of 2025, Xishan Technology achieved an operating income of 155 million yuan, a year-on-year increase of 2.40%, but the net profit attributable to the parent company decreased by 41.62% to 34.38 million yuan [2] Group 3 - Since its A-share listing, Xishan Technology has distributed a total of 94.07 million yuan in dividends [3]

Group 1 - The board of directors of Chongqing Xishan Technology Co., Ltd. received a resignation report from director Zhang Weiya, who is resigning due to work relocation [1] - Zhang Weiya's resignation does not result in the board's member count falling below the legal minimum and will not affect the normal operation of the board [1] - Zhang Weiya did not hold any shares in the company during her tenure and has positively contributed to the company's governance [1] Group 2 - The company expresses gratitude for Zhang Weiya's contributions during her time as a director [1]

Group 1 - The core point of the article is that Xishan Technology announced the resignation of board member Zhang Weiya due to work relocation [2] - The resignation was formally submitted through a report to the company's board of directors [2] - The announcement was made on the evening of September 19 [2] Group 2 - The company is undergoing a change in its board composition with the departure of a key member [2] - Zhang Weiya's resignation may impact the company's strategic direction and governance [2] - The reason for the resignation is attributed to work relocation, indicating potential changes in her professional commitments [2]

Group 1 - The core point of the news is that Zhang Weiya has resigned from her position as a director of Xishan Technology due to work relocation [1] - Xishan Technology's revenue composition for the year 2024 is as follows: 98.57% from medical devices, 1.4% from other sources, and 0.03% from additional business activities [1] - As of the report, Xishan Technology has a market capitalization of 3 billion yuan [2]

证券代码：688576 证券简称：西山科技 公告编号：2025-040 重庆西山科技股份有限公司 关于公司董事辞任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 重庆西山科技股份有限公司（以下简称"公司"）董事会于近日收到公司董 事张威亚女士的《关于辞去董事职务的辞职报告》，张威亚女士因工作调动原因 申请辞去公司董事职务。根据《公司法》《公司章程》及有关法律法规的规定， 张威亚女士的辞任申请自辞职报告送达公司董事会时生效，张威亚女士辞任未导 致公司董事会成员人数低于法定人数，不会影响公司董事会的正常运行，其职务 变动不会对公司正常经营活动产生不利影响。 | 是否存在 | 是否继续在上 | 原定任期 | 具体职务 | 未履行完 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 姓名 | 辞任职务 | 辞任时间 | 离任原因 | 市公司及其控 | 到期日 | ...

Core Viewpoint - Xishan Technology (688576.SH) faces potential joint compensation claims exceeding 35.71 million yuan due to alleged price inflation of medical devices recognized by the 301 Hospital of the People's Liberation Army [1][2] Group 1: Arbitration Claims - The arbitration claims from China National Pharmaceutical Group United Medical Devices Co., Ltd. and China National Pharmaceutical Group Beijing United Meidi Medical Devices Co., Ltd. total approximately 35.71 million yuan, with specific compensation obligations and amounts yet to be determined [1][2] - The claims include a demand for the return of over 20.3 million yuan due to price inflation for medical consumables delivered to the 301 Hospital from June 2019 to October 2021 [2] Group 2: Company Financials - In the first half of 2025, Xishan Technology reported revenue of 155 million yuan and a net profit of 34.38 million yuan, indicating that the arbitration amount exceeds the company's net profit for that period [3] - The company specializes in minimally invasive surgical medical devices and has established itself as a leading player in the surgical power device sector in China, with products sold to nearly a thousand tertiary hospitals [3] Group 3: IPO Implications - The timing of the arbitration claims is notable as they were made in 2023, coinciding with Xishan Technology's IPO application, which could impact the company's ability to go public and its financial metrics [4] - The company's prospectus details that pricing for products is determined by distributors and hospitals through bidding processes, indicating that Xishan Technology does not participate in end pricing [4][5] Group 4: Distributor Relationships - The distributor involved, Dejuhe Medical Technology Co., Ltd., was not among Xishan Technology's top five distributors from 2020 to 2022, raising questions about the claims of joint liability for price inflation [5]

Group 1 - The core viewpoint of the news highlights the positive performance of the AI-focused ETF, with a 0.75% increase and significant trading activity, indicating a strong market interest in AI-related stocks [1][2] - Key stocks within the ETF include Stone Technology, which rose by 5.93%, Lingyun Optics with a 4.58% increase, and Sikan Technology up by 3.69%, showcasing the strong performance of leading companies in the AI sector [1] - The overall trading volume exceeded 21 million yuan, reflecting active market participation and robust liquidity [1] Group 2 - Huawei's announcement on September 16 outlines ten major technological trends for an intelligent world by 2035, predicting a 100,000-fold increase in total computing power and significant innovations in computing architecture and paradigms [1] - According to招商证券, both domestic and international demand for computing power remains high, with global AI infrastructure spending continuing at elevated levels, as evidenced by Nvidia's FY26Q2 performance meeting expectations [1] - Domestic computing companies are expected to continue delivering strong results, with recent developments such as Cambrian's capital increase approval and Haiguang's acquisition progress indicating confidence in future performance [1]

Core Viewpoint - Chongqing Xishan Technology Co., Ltd. is involved in arbitration matters, with the arbitration tribunal having accepted the case but not yet convened. The company is one of the respondents and may bear joint liability for compensation [1] Group 1: Arbitration Details - The company has received materials related to two arbitration cases from the Beijing Arbitration Commission, with the claimants being China National Pharmaceutical Group United Medical Devices Co., Ltd. (referred to as "Guoyao United") and China National Pharmaceutical Group Beijing United Meidi Medical Devices Co., Ltd. (referred to as "Guoyao Beijing United Meidi") [2] - In the first arbitration case, Guoyao United claims that it is not at fault for the pricing issues related to medical supplies delivered to 301 Hospital, which were found to exceed the national minimum price, and seeks joint compensation of 20.300398 million yuan and legal fees of 630,000 yuan from the respondents [2] - In the second arbitration case, Guoyao Beijing United Meidi similarly claims it is not responsible for the pricing issues and seeks joint compensation of 14.2746 million yuan and legal fees of 509,400 yuan from the respondents [2] Group 2: Company Response - The company's board has begun organizing defense materials and has hired a professional legal team to actively respond to the arbitration [3] - The company asserts that the pricing of the medical supplies in question was in line with commercial practices and found no evidence of inflated prices [3] - Initial legal consultations suggest that the arbitration cases are not expected to have a significant impact on the company's daily operations [3]